UK NICE Expands Access to Spinraza for SMA Type 3

UK NICE Expands Access to Spinraza for SMA Type 3

293612

UK NICE Expands Access to Spinraza for SMA Type 3

A decision from England’s National Institute for Health and Care Excellence (NICE) will make Spinraza (nusinersen) available to people with spinal muscular atrophy (SMA) type 3 who are unable to walk. In England, Spinraza is available through a managed access agreement (MAA) between NICE, the National Health Service (NHS, England’s publicly funded healthcare system), and Biogen, Spinraza’s manufacturer. The MAA allows patients to be treated with Spinraza, while also continuing to collect data on the…

You must be logged in to read/download the full post.